Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Conditions
Meibomian Gland Dysfunction
Interventions
iLux 2020 System, LipiFlow Pulsation System
Device
Lead sponsor
Tear Film Innovations, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Diego, California + 4 more
Conditions
Thymidine Kinase 2 (TK2)
Interventions
dC/dT
Drug
Lead sponsor
Zogenix MDS, Inc.
Industry
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Contact Lens Comfort Relative to Meibomian Gland Status

NCT01819194
Conditions
Meibomian Gland Dysfunction
Interventions
senofilcon A
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fullerton, California
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
Interventions
Tixel C, LipiFlow
Device
Lead sponsor
Novoxel Ltd.
Industry
Eligibility
22 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
La Jolla, California • Newport Beach, California • Kansas City, Missouri + 2 more
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Blepharitis
Interventions
Erythromycin, Besifloxocin
Drug
Lead sponsor
John, George, M.D.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational

Lacrimal Drainage Resistance Study

NCT01766232
Conditions
Epiphora, Nasolacrimal Duct Obstruction, Canalicular Stenosis, Functional Tear Pump Failure, Ectropion
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Terminated No phase listed Observational Accepts healthy volunteers

Photic Blink Reflex in People With Blepharospasm and Increased Blinking

NCT03263000
Conditions
Blepharospasm
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Blepharospasm
Interventions
incobotulinumtoxinA (Xeomin), Placebo
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Periorbital Edema
Interventions
AccuTite, AccuTite + Morpheus 8
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
29 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Sarasota, Florida • Youngstown, Ohio
Conditions
Cervical Dystonia, Blepharospasm
Interventions
Xeomin®
Biological
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
70
States / cities
Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 60 more
Conditions
Paralytic Lagophthalmos, Corneal Exposure
Interventions
temporary magnetic system for tarsorrhaphy (MST)
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 3 Interventional Accepts healthy volunteers

Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

NCT05945615
Conditions
Blepharoptosis, Synkinesis, Hyperkinesis, Facial Paralysis
Interventions
Oxymetazoline 0.1% (Pf) Oph Soln Ud, Preservative free lubricating drops
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hershey, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

LEV102 Topical Gel in Acquired Blepharoptosis

NCT05715346
Conditions
Acquired Blepharoptosis
Interventions
LEV102 1.0%, LEV102 2.0%, Vehicle
Drug
Lead sponsor
Levation Pharma, Ltd.
Industry
Eligibility
25 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Newport Beach, California • Nashville, Tennessee
Conditions
Eyelid Diseases, Eyelid Movement Disorders, Dry Eye, Dry Eye Syndromes, Skin Laxity
Interventions
TriLift device
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Contact Lens Discomfort, Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
Bruder Moist Heat Compress, Washcloth
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Not applicable Interventional Results available

Clinical Trial to Improve the Magnetic Levator Prosthesis

NCT03818204
Conditions
Blepharoptosis, Ptosis, Eyelid, Myasthenia Gravis, Stroke, Traumatic Brain Injury
Interventions
Magnetic Levator Prosthesis (MLP)
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
4 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Blepharospasm
Interventions
No intervention- only one time survey
Other
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 81 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Fountain Valley, California • Sarasota, Florida • Boston, Massachusetts + 2 more
Conditions
Blepharitis
Interventions
Avenova Lid Cleanser
Device
Lead sponsor
Minnesota Eye Consultants, P.A.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bloomington, Minnesota
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions
Vehicle of TP-03
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Northridge, California • Shelby, North Carolina
Conditions
Blepharospasm
Interventions
Botulinum toxin type A
Biological
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
14
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more
Completed Phase 1 Interventional Results available

Demodex Blepharitis Treatment Study

NCT01647217
Conditions
Chronic Blepharitis
Interventions
Terpinen-4-ol, Placebo
Drug · Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
15 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami, Florida